EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas

Soomin Ahn iD, Inwoo Hwang iD, Kyoung-Mee Kim iD

Journal of Gastric Cancer · 2025 · 25 (4) · 639

DOI: 10.5230/jgc.2025.25.e47 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastric Cancer, 2025. Verfasst von Soomin Ahn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Receptor, Fibroblast Growth Factor, Type 2, Claudins, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MOHW, NRF, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Claudin 18.2 (CLDN18.2) and fibroblast growth factor receptor 2b (FGFR2b) have recently emerged as promising therapeutic targets for advanced gastric cancer (GC). Before integrating CLDN18.2 and FGFR2b into routine practice, for optimal treatment planning, it is important to consider whether there exists an overlap between these biomarkers. MATERIALS AND METHODS: We evaluated CLDN18.2 expression in many patients with GC (n=1,538) using tissue microarrays that had been previously used to evaluate FGFR2b overexpression. We investigated the overlap between CLDN18.2 and FGFR2b expression and evaluated the clinicopathological features and prognostic implications of CLDN18.2 expression. RESULTS: The CLDN18.2 positivity rates at 50% and 75% cutoffs were 34.7% and 24.4%, respectively. Heterogeneous expression was identified in 335 (23.5%) of 1426 cases with multiple tissue microarray cores. FGFR2b positivity at >0% cutoff was identified in 47 (3.1%) patients with more marked intratumoral heterogeneity than that observed with CLDN18.2. CLDN18.2 positivity (59.6%) in FGFR2b-positive GCs was significantly higher than that (33.9%) in FGFR2b-negative GCs (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsReceptor, Fibroblast Growth Factor, Type 2ClaudinsBiomarkers, TumorHumansMaleFemaleMiddle AgedTissue Array AnalysisAgedPrognosisAdultAged, 80 and over

Stichwörter der Autor:innen

Claudin-18Fibroblast growth factor receptor 2ImmunohistochemistryStomach neoplasms

Substanzen

Receptor, Fibroblast Growth Factor, Type 2ClaudinsFGFR2 protein, humanBiomarkers, TumorCLDN18 protein, human

Autor:innen und Institutionen

  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kkmkys@skku.edu.

ORCID-Profile: Soomin Ahn, Inwoo Hwang, Kyoung-Mee Kim

Förderung

  • MOHW
  • NRF
  • Ministry of Health and Welfare
  • National Research Foundation of Korea

Zitieren

APA

Ahn, S., Hwang, I., & Kim, K. M. (2025). Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas. Journal of Gastric Cancer, 25(4), 639. https://doi.org/10.5230/jgc.2025.25.e47

Vancouver

Ahn S, Hwang I, Kim KM. Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas. Journal of Gastric Cancer. 2025;25(4):639. doi:10.5230/jgc.2025.25.e47

BibTeX
@article{Ahn2025,
  author = {Ahn, Soomin and Hwang, Inwoo and Kim, Kyoung-Mee},
  title = {Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas},
  journal = {Journal of Gastric Cancer},
  year = {2025},
  volume = {25},
  number = {4},
  pages = {639},
  doi = {10.5230/jgc.2025.25.e47}
}
Kostenlos starten →